Caroline Schnakers1, Martin M Monti. 1. aResearch Institute, Casa Colina Hospital and Centers for Healthcare, Pomona bDepartment of Psychology cBrain Injury Research Center (BIRC), Department of Neurosurgery, University of California Los Angeles, Los Angeles, California, USA.
Abstract
PURPOSE OF REVIEW: Very few options exist for patients who survive severe traumatic brain injury but fail to fully recover and develop a disorder of consciousness (e.g. vegetative state, minimally conscious state). RECENT FINDINGS: Among pharmacological approaches, Amantadine has shown the ability to accelerate functional recovery. Although with very low frequency, Zolpidem has shown the ability to improve the level of consciousness transiently and, possibly, also in a sustained fashion. Among neuromodulatory approaches, transcranial direct current stimulation has been shown to transiently improve behavioral responsiveness, but mostly in minimally conscious patients. New evidence for thalamic deep brain stimulation calls into question its cost/benefit trade-off. SUMMARY: The growing understanding of the biology of disorders of consciousness has led to a renaissance in the development of therapeutic interventions for patients with disorders of consciousness. High-quality evidence is emerging for pharmacological (i.e. Amantadine) and neurostimulatory (i.e. transcranial direct current stimulation) interventions, although further studies are needed to delineate preconditions, optimal dosages, and timing of administration. Other exciting new approaches (e.g. low intensity focused ultrasound) still await systematic assessment. A crucial future direction should be the use of neuroimaging measures of functional and structural impairment as a means of tailoring patient-specific interventions.
PURPOSE OF REVIEW: Very few options exist for patients who survive severe traumatic brain injury but fail to fully recover and develop a disorder of consciousness (e.g. vegetative state, minimally conscious state). RECENT FINDINGS: Among pharmacological approaches, Amantadine has shown the ability to accelerate functional recovery. Although with very low frequency, Zolpidem has shown the ability to improve the level of consciousness transiently and, possibly, also in a sustained fashion. Among neuromodulatory approaches, transcranial direct current stimulation has been shown to transiently improve behavioral responsiveness, but mostly in minimally conscious patients. New evidence for thalamic deep brain stimulation calls into question its cost/benefit trade-off. SUMMARY: The growing understanding of the biology of disorders of consciousness has led to a renaissance in the development of therapeutic interventions for patients with disorders of consciousness. High-quality evidence is emerging for pharmacological (i.e. Amantadine) and neurostimulatory (i.e. transcranial direct current stimulation) interventions, although further studies are needed to delineate preconditions, optimal dosages, and timing of administration. Other exciting new approaches (e.g. low intensity focused ultrasound) still await systematic assessment. A crucial future direction should be the use of neuroimaging measures of functional and structural impairment as a means of tailoring patient-specific interventions.
Authors: John C O'Donnell; Kevin D Browne; Todd J Kilbaugh; H Isaac Chen; John Whyte; D Kacy Cullen Journal: Neurosci Biobehav Rev Date: 2018-12-11 Impact factor: 8.989
Authors: Evan S Lutkenhoff; Matthew J Wright; Vikesh Shrestha; Courtney Real; David L McArthur; Manuel Buitrago-Blanco; Paul M Vespa; Martin M Monti Journal: Neurology Date: 2020-09-09 Impact factor: 9.910
Authors: Carlo Cavaliere; Sivayini Kandeepan; Marco Aiello; Demetrius Ribeiro de Paula; Rocco Marchitelli; Salvatore Fiorenza; Mario Orsini; Luigi Trojano; Orsola Masotta; Keith St Lawrence; Vincenzo Loreto; Blaine Alexander Chronik; Emanuele Nicolai; Andrea Soddu; Anna Estraneo Journal: Front Neurol Date: 2018-10-18 Impact factor: 4.003
Authors: Joshua A Cain; Shakthi Visagan; Micah A Johnson; Julia Crone; Robin Blades; Norman M Spivak; David W Shattuck; Martin M Monti Journal: Sci Rep Date: 2021-03-17 Impact factor: 4.379
Authors: Josh A Cain; Norman M Spivak; John P Coetzee; Julia S Crone; Micah A Johnson; Evan S Lutkenhoff; Courtney Real; Manuel Buitrago-Blanco; Paul M Vespa; Caroline Schnakers; Martin M Monti Journal: Brain Sci Date: 2022-03-23
Authors: Andrea I Luppi; Joshua Cain; Lennart R B Spindler; Urszula J Górska; Daniel Toker; Andrew E Hudson; Emery N Brown; Michael N Diringer; Robert D Stevens; Marcello Massimini; Martin M Monti; Emmanuel A Stamatakis; Melanie Boly Journal: Neurocrit Care Date: 2021-07-08 Impact factor: 3.210